Brinzolamide/timolol: In open-angle glaucoma and ocular hypertension

Abstract

▲ Brinzolamide 1timolol 0.5 fixed combination (brinzolamidetimolol) is a twice-daily eyedrops suspension comprising the carbonic anhydrase-II inhibitor brinzolamide and the β-adrenergic receptor antagonist timolol. ▲ Brinzolamidetimolol produced clinically relevant reductions in mean intraocular pressure (IOP) from baseline and was more effective than brinzolamide or timolol monotherapy in lowering IOP in a 6-month, randomized, phase III trial in patients with open-angle glaucoma or ocular hypertension (n523). The proportion of patients achieving a mean IOP of <18mmHg was significantly greater in recipients of brinzolamidetimolol than in recipients of brinzolamide or timolol monotherapy. ▲ The IOP-lowering efficacy of brinzolamidetimolol was maintained for up to 12 months, and was no less effective than dorzolamide 2timolol 0.5 solution (dorzolamidetimolol) in a randomized, phase III, noninferiority trial (n437). ▲ Brinzolamidetimolol was generally well tolerated and was associated with significantly lower ocular discomfort scores than dorzolamidetimolol. Moreover, a significantly greater number of patients expressed a preference for brinzolamidetimolol over dorzolamidetimolol. The main ocular adverse event was blurred vision, and was not considered to be a safety issue. © 2009 Adis Data Information BV. All rights reserved.